March’s Myeloma Action Month means sharing patient milestones
This year’s Myeloma Action Month (MAM), which is observed each March, is focused on celebrating and sharing patient milestones to help call…
News
EU committee recommends Jaypirca for certain leukemia patients
A European Medicines Agency (EMA) committee recommended that Jaypirca (pirtobrutinib) be approved to treat some adult patients with chronic lymphocytic leukemia (CLL), a type of…
Immunotherapy shows promise as treatment for pancreatic cancer
Treatment with CAN-2409, an immune-modulating anticancer therapy, showed promising trends toward improved survival in a Phase 2 clinical trial involving people with pancreatic cancer,…
Phase 1b/2 trial of CLD-101 for aggressive glioma now recruiting
Calidi Biotherapeutics has begun recruiting adults with high-grade glioma for a Phase 1b/2 clinical trial to study the effects of multiple doses of…
New Phase 2 dosing of stenoparib to start testing in ovarian cancer
Allarity Therapeutics will soon start recruiting patients at several U.S. sites for a new dosing protocol in its Phase 2 trial testing stenoparib…
High-risk genetic changes with myeloma tied to poorer outcomes
The presence of more than one high-risk genetic abnormality is associated with dramatically more aggressive multiple myeloma, a study reported. Its findings highlight the…
Tuspetinib study in newly diagnosed AML moves to higher dose
Aptose Biosciences will be testing a higher dose of tuspetinib as part of a triple-combination regimen that’s being explored in a clinical trial…
Low muscle mass linked to worse outcomes with chemoradiotherapy
Low muscle mass in people with inoperable pancreatic cancer undergoing chemoradiotherapy, or CRT, was linked with more treatment-related toxicities and shorter overall survival in…
Dordaviprone under FDA priority review for aggressive glioma type
The U.S. Food and Drug Administration (FDA) has agreed to a priority review of a Chimerix application seeking accelerated approval of dordaviprone, its oral…
FDA decision on linvoseltamab in treating RRMM expected in July
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Regeneron Pharmaceuticals seeking the approval of linvoseltamab to treat…
